Neutra Corp. (NTRR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 243.82 Thousand USD | -26.78% |
| 2023 | 332.98 Thousand USD | -45.83% |
| 2022 | 614.74 Thousand USD | 38.02% |
| 2021 | 445.4 Thousand USD | 11.17% |
| 2020 | 400.64 Thousand USD | -76.56% |
| 2019 | 1.7 Million USD | 944.26% |
| 2018 | 163.68 Thousand USD | -55.85% |
| 2017 | 370.72 Thousand USD | -64.22% |
| 2016 | 1.03 Million USD | 62.93% |
| 2015 | 635.86 Thousand USD | -34.17% |
| 2014 | 965.9 Thousand USD | 213.55% |
| 2013 | 308.05 Thousand USD | 279.3% |
| 2012 | 81.21 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 53.31 Thousand USD | -27.41% |
| 2024 Q1 | 74.01 Thousand USD | 21.84% |
| 2024 Q4 | 36.61 Thousand USD | -31.32% |
| 2024 FY | 195.58 Thousand USD | -41.26% |
| 2024 Q2 | 73.45 Thousand USD | -0.76% |
| 2023 Q2 | 98.9 Thousand USD | 2.4% |
| 2023 FY | 332.98 Thousand USD | -45.83% |
| 2023 Q3 | 76.74 Thousand USD | -22.4% |
| 2023 Q1 | 96.58 Thousand USD | -49.01% |
| 2023 Q4 | 60.74 Thousand USD | -20.85% |
| 2022 Q1 | 123.99 Thousand USD | -41.03% |
| 2022 Q4 | 189.41 Thousand USD | 7.16% |
| 2022 Q2 | 124.57 Thousand USD | 0.47% |
| 2022 FY | 614.74 Thousand USD | 38.02% |
| 2022 Q3 | 176.76 Thousand USD | 41.89% |
| 2021 Q3 | 94.94 Thousand USD | 5.88% |
| 2021 Q4 | 210.25 Thousand USD | 121.45% |
| 2021 Q2 | 89.67 Thousand USD | 77.46% |
| 2021 FY | 445.4 Thousand USD | 11.17% |
| 2021 Q1 | 50.53 Thousand USD | -46.92% |
| 2020 FY | 400.64 Thousand USD | -76.56% |
| 2020 Q4 | 95.2 Thousand USD | -47.34% |
| 2020 Q1 | 66.95 Thousand USD | -11.78% |
| 2020 Q2 | 57.7 Thousand USD | -13.81% |
| 2020 Q3 | 180.78 Thousand USD | 213.3% |
| 2019 Q1 | 63.85 Thousand USD | 34.71% |
| 2019 FY | 1.7 Million USD | 944.26% |
| 2019 Q4 | 75.89 Thousand USD | -94.96% |
| 2019 Q3 | 1.5 Million USD | 2317.34% |
| 2019 Q2 | 62.34 Thousand USD | -2.35% |
| 2018 Q4 | 47.39 Thousand USD | 83.42% |
| 2018 Q3 | 25.84 Thousand USD | -25.18% |
| 2018 FY | 163.68 Thousand USD | -55.85% |
| 2018 Q1 | 55.9 Thousand USD | -41.22% |
| 2018 Q2 | 34.53 Thousand USD | -38.22% |
| 2017 Q1 | 114.35 Thousand USD | -82.3% |
| 2017 Q2 | 94.1 Thousand USD | -17.7% |
| 2017 Q3 | 67.16 Thousand USD | -28.63% |
| 2017 FY | 370.72 Thousand USD | -64.22% |
| 2017 Q4 | 95.1 Thousand USD | 41.61% |
| 2016 Q2 | 109.87 Thousand USD | -19.21% |
| 2016 FY | 1.03 Million USD | 62.93% |
| 2016 Q1 | 136.01 Thousand USD | 11.63% |
| 2016 Q4 | 646.17 Thousand USD | 348.83% |
| 2016 Q3 | 143.96 Thousand USD | 31.03% |
| 2015 Q3 | 164 Thousand USD | -22.51% |
| 2015 Q2 | 211.63 Thousand USD | 1.56% |
| 2015 Q1 | 208.38 Thousand USD | -19.97% |
| 2015 FY | 635.86 Thousand USD | -34.17% |
| 2015 Q4 | 121.84 Thousand USD | -25.71% |
| 2014 Q2 | 242.68 Thousand USD | 29.54% |
| 2014 FY | 965.9 Thousand USD | 213.55% |
| 2014 Q3 | 273.51 Thousand USD | 12.7% |
| 2014 Q1 | 187.34 Thousand USD | 138.56% |
| 2014 Q4 | 260.37 Thousand USD | -4.8% |
| 2013 Q2 | 97.78 Thousand USD | 20.57% |
| 2013 Q3 | 50.64 Thousand USD | -48.21% |
| 2013 Q4 | 78.52 Thousand USD | 55.06% |
| 2013 FY | 308.05 Thousand USD | 279.3% |
| 2013 Q1 | 81.09 Thousand USD | 36.32% |
| 2012 Q2 | 17.38 Thousand USD | 2977.35% |
| 2012 FY | 81.21 Thousand USD | 0.0% |
| 2012 Q1 | 565.00 USD | 0.0% |
| 2012 Q4 | 59.49 Thousand USD | 1477.2% |
| 2012 Q3 | 3772.00 USD | -78.31% |
| 2011 FY | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 81.742% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 95.164% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.175% |
| Nascent Biotech, Inc. | 2.22 Million USD | 89.066% |
| Rebus Holdings, Inc. | 664 Thousand USD | 63.28% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.346% |
| Qrons Inc. | 643.67 Thousand USD | 62.121% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 37.412% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.576% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 41.316% |
| Skye Bioscience, Inc. | 13.54 Million USD | 98.2% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.719% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 95.042% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 6.841% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.715% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 91.639% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 83.766% |
| Mesoblast Limited | 5.9 Million USD | 95.869% |
| Marizyme, Inc. | 19.23 Million USD | 98.733% |
| Genus plc | 147.7 Million USD | 99.835% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 97.223% |
| Pharming Group N.V. | 225.49 Million USD | 99.892% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 88.099% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 81.825% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 97.076% |
| ContraFect Corporation | 56.88 Million USD | 99.571% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 94.47% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 83.512% |
| IMV Inc. | 37.7 Million USD | 99.353% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 91.262% |
| MultiCell Technologies, Inc. | 567.42 USD | -42870.11% |
| ONE Bio Corp. | 6.44 Million USD | 96.216% |
| Accustem Sciences Inc. | 3.74 Million USD | 93.492% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.716% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 54.166% |
| Q BioMed Inc. | 3.43 Million USD | 92.905% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.013% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 90.72% |
| Biomind Labs Inc. | 994.18 Thousand USD | 75.475% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.755% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 86.144% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 96.371% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 86.922% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1075.284% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 98.477% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 86.713% |
| GB Sciences, Inc. | 1.42 Million USD | 82.836% |
| Alpha Cognition Inc. | 9.7 Million USD | 97.488% |
| HST Global, Inc. | 140.9 Thousand USD | -73.037% |
| CSL Limited | 3.44 Billion USD | 99.993% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 78.325% |
| Halberd Corporation | 74.84 Thousand USD | -225.781% |
| Enzolytics Inc. | 2.17 Million USD | 88.813% |
| Agentix Corp. | 1.37 Million USD | 82.226% |
| Resverlogix Corp. | 12.71 Million USD | 98.082% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 93.321% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.984% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 76.645% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 89.862% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 84.562% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 92.839% |
| AVAX Technologies, Inc. | 7.31 Million USD | 96.665% |
| Zenith Capital Corp. | 8.94 Million USD | 97.274% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.97% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -1299.581% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 90.07% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -42.162% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 87.307% |
| Kadimastem Ltd | 2.41 Million USD | 89.883% |
| Helix BioMedix, Inc. | 1.97 Million USD | 87.636% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 97.756% |
| BioStem Technologies, Inc. | 22.97 Million USD | 98.939% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -34.348% |
| LadRx Corporation | 3.81 Million USD | 93.604% |
| Cell Source, Inc. | 4.32 Million USD | 94.363% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 73.598% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 73.598% |
| NovAccess Global Inc. | 2.46 Million USD | 90.116% |
| Affymax, Inc. | 39.38 Million USD | 99.381% |
| Itoco Inc. | 919.14 Thousand USD | 73.473% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 94.247% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 78.211% |
| Mobile Lads Corp. | 554.54 Thousand USD | 56.032% |
| CytoDyn Inc. | 18.05 Million USD | 98.65% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -868.735% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -10.788% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 82.827% |
| SYBLEU INC | 160.87 Thousand USD | -51.558% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 86.576% |
| International Stem Cell Corporation | 5.27 Million USD | 95.374% |
| Bioxytran, Inc. | 3.82 Million USD | 93.617% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -363.168% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1098.55% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.328% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 84.931% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 66.865% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 92.163% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 98.603% |
| PureTech Health plc | 144.59 Million USD | 99.831% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 98.81% |
| IXICO plc | 4.7 Million USD | 94.82% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 97.228% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.793% |
| CSL Limited | 3.89 Billion USD | 99.994% |
| Cellectis S.A. | 97.32 Million USD | 99.749% |